Overview

Riluzole Effects on Hippocampus Biomarkers

Status:
Completed

Trial end date:
2019-03-16

Target enrollment:

Participant gender:

Summary

To examine the clinical efficacy of the anti-glutamatergic medication riluzole in posttraumatic stress disorder (PTSD), and its effect on hippocampus biomarkers that our laboratory previously has identified using MRS.

Phase:

Early Phase 1

Details

Lead Sponsor:

Mclean Hospital

Collaborator:

Brain & Behavior Research Foundation

Treatments:

Riluzole